Tamarix Pharma

Tamarix Pharma was founded in 2021 based on technology licensed from the National Institute for Biotechnology in the Negev (Israel) and is focused on developing novel technologies that restore physiological balance in apoptosis-related diseases.

The company’s lead assets, VBIT-4 and VBIT-12, are small molecules designed to target a key mitochondrial process known as VDAC1 oligomerization. VDAC1 oligomerization is a key process involved in apoptotic cell death that has been validated by multiple independent research groups as an anti-apoptotic target.

According to the company its unique mechanism of action represents a highly-differentiated approach to potentially treating a variety of acute and chronic conditions resulting from apoptotic cell death. Early exploration of indications for VBIT-4 and VBIT-12 will include: dry age-related macular degeneration (dry AMD) / geographic atrophy (GA); low-tension glaucoma – intraocular pressure (IOP) independent therapy; and central vein occlusion.

Tamarix plans to be Phase I ready by the end of 2023 and is says it is currently expanding its investor base to support development of VBIT-4 (primary focus) and VBIT-12.

Subscribe for alerts on new companies featured on Startups.Bio

MxT Biotech
MxT Biotech, a Korea University spin-out, aims to transform cancer immunotherapy, cellular engineering and genome editing with its patented non-viral genome editing technology. The Hydroporator™ is a non-viral microfluidic platform …
Vilya
Vilya is a spin-out of the University of Washington Institute for Protein Design (IPD), with a platform to design membrane-permeable peptides with high structural accuracy, opening up a new class …
VentureRadar’s Top 100 Emerging Biotech Start-ups Report
Biotechnology is in the midst of a exciting era of innovation, with an ever-expanding toolbox of modalities and approaches spawning development of exciting new vaccines, medicines and therapies. VentureRadar's Top …
CorriXR Therapeutics
CorriXR Therapeutics is an oncology-focused biotherapeutics developing a novel gene editing platform technology. CorriXR has developed an innovative CRISPR/Cas molecule that disables the genome of a tumor cell but not …

View all recently featured startups

Tags: